A therapeutic pipeline targeting unmet clinical needs in Oncology and Autoimmune disease
Six approved CAR T cell products expected to generate
>$4B in 2024 (>25% CAGR through 2028)1
However, approved indications limited to B-cell malignancies, and progression free survival is not achieved for most patients
Current limitations create enormous unmet need; robust opportunity exists
Cell therapies target
just 5% of cancers
By unlocking CAR-T efficacy for difficult to treat diseases in both oncology and autoimmune indications
Progression-free survival <40%
with the utilization of novel gene editing technologies
Approved cell therapies are associated with prolonged/permanent B-cell aplasia
by preventing on-target aplasia, lowering dosing, reducing vein-to-vein times, specifically targeting malignant cells
Currently cell therapies target
just 5% of cancers
Cancer & Autoimmunity: by expanding antigenic targets
Progression-free survival <40%
via utilization of novel gene editing technologies
Cell therapies are associated with prolonged/permanent B cell aplasia
by preventing on-target aplasia, lowering dosing, reducing vein-to-vein times, specifically targeting malignant cells
• Augment effector function by utilizing gene editing of the CD5 signaling pathway to exploit its immuno-modulatory properties
• Enhance early CAR-T in vivo expansion and functional persistence by enhancing “stemness” and durability
• Deliver superior anti-tumor efficacy in both liquid and solid tumor animal models versus conventional cell therapies
• Improve patient outcomes by lowering dosing requirements, reducing manufacturing failures, and expanding successful applications of engineered T-cell therapies
Source: Adapted from Mordor Intelligence | Data from UK Haematology Malignancy Research Network Smith et al. Br J Cancer (2015) 112, 1575-1584
• Generating POC clinical data for our Viper 101 lead program in a cost-effective manner. Will validate safety and efficacy of both Viper 101 and Senza5 platform technology.
Expect expedited path to approval
• Employing novel gene editing technologies (NGET) via a strategic partnership with industry leader Metagenomi to power a pipeline of next-generation gene-edited cell therapy assets
• Developing pipeline programs to exploit our enabling technologies and generate highly differentiated, innovative cellular therapeutics
• Harvesting the utility of our platform technologies to drive paradigm-shifting improvements in cell therapy dosing, delivery, pre-conditioning regimens and vein-to-vein times
• Leveraging Viper 101 POC clinical data to attract strategic partners and explore monetizing lead program and platform technologies via out-licensing
Chief Executive Officer,
Co-Founder & Director
Chief Medical Officer
Sr. Director, CMC
Head, Preclinical Development
Director, Laboratory Operations
Sr. Controller
Chief Executive Officer,
Co-Founder & Director
Co-Founder & Chairman
Director
Director
Observer
General Partner, Humboldt Fund
Observer
Director of Penn Medicine
Co-Investment Fund
Scientific Founder & SAB Chair
Scientific Advisor
Scientific Advisor
Scientific Advisor
Scientific Advisor
Scientific Advisor
Principal Investigator, Clinical Trial
